Close menu

 

 

HEPHAISTOS-Pharma secures a €2 million seed round with xista science ventures, Foundation Fournier-Majoie and Noshaq

 

  • 1st institutional round for HEPHAISTOS-Pharma, getting on track to bring its lead product ONCO-Boost to the clinic.
  • ONCO-Boost is a novel class of TLR4 immunostimulants that turn cold tumors into hot ones, increasing the efficacy of other therapies, notably immune-checkpoint inhibitors.

 

 

Read the press release

More information